Demand for new types of drugs is growing, as anti -drug diseases and emerging diseases are becoming a global health threat. Researchers are in the process of re -examining some of the microbes that serve as the most important source of medicine: actinomycetes.
Scientists at the University of Washington at St. Louis and the University of Hawaiʻi identified a candidate for the development of a drug from one of these microbes, a soil bacterium called Compare flaviverrucosa. They presented their findings in a study published in the week of April 11 in Proceedings of the National Academy of Sciences.
“Few actinomycetes are an unused source of new bioactive compounds,” said Joshua Blodgett, professor of biology at Arts & Science, author of the new study. “Our genomics techniques have allowed us to identify a common peptide for future drug design projects.”
Actinomycetes form bioactive compounds that are the basis for many drugs, especially antibiotics and anticancer drugs. Since the 1940s, pharmaceutical companies have analyzed common actinomycetes to see what they do. Today, about two -thirds of all drugs used in hospitals and clinics receive a portion from actinomycetes.
But some of these microbes – known as the rare actinomycetes – have been listed but have not been widely studied to date.
The definition of “rare” isn’t set out in rock, but these actinomycetes are more complex in nature than others, and they can grow slowly, Blodgett said. For these and other reasons, a few actinomycetes have not been fully reported for clinical and biotechnology applications.
Among the few actinomycetes, Compare flaviverrucosa said Blodgett.
“It has a different biology, adaptation for a different enzymology, directs the action of an unexpected chemical, which is stored in an unobserved group of bacteria,” he said.
Blodgett and his colleagues, co -author Shugeng Cao at the University of Hawaiʻi, found that this rare actinomycete produces molecules that fight a certain type of human ovarian disease, fibrosarcoma. prostate cancer and leukemia cell lines.
Scientists already know Compare flaviverrucosa when they went to look for a few actinomycetes with a genetic code that showed they could produce piperazyl molecules. These molecules are incorporated into a separate building block as a standard for similar applications in medicine, Blodgett said.
But when the researchers dug deeper, they discovered some amazing things.
“At a higher level, it’s seen as if a piece of the genome can make two genes.” Usually, we think of a group of genes, groups of genes that are similar. as well as blueprints for the production of such molecules as medicine.
The first signs confirmed the accuracy. Using a combination of new metabolomics with chemical and biological technologies, Blodgett and team were able to show this rare actinomycete to actually produce two different bioactive molecules from a group of genes called supercluster.
Superclusters are not small in biology. This type of supercluster is applied to two different molecules that are subsequently bonded to an atypical chemical reaction.
“Nature connects two different things,” Blodgett said. “And, as it turns out, against all sorts of disease phone lines, when you connect A and B, it becomes a lot stronger.”
Separate strong antibiotic agents from weak ones
Identification of common piperazyl dimeric cyclopeptides bound by a DSM 44664 biosynthetic supercluster, Proceedings of the National Academy of Sciences (2022). DOI: 10.1073 / pnas.2117941119.
Presented by Washington University at St. Louis
Directions: From a rare soil microbe, a new antibiotic candidate (2022, April 11) downloaded on 11 April 2022 from https://phys.org/news/2022-04-rare-soil-microbe-antibiotic-candidate .html
This document is copyrighted. Except for appropriate action for the purpose of personal inquiry or research, no piece may be reproduced without permission. Information is provided for informational purposes only.